Dr. Robert Kiss is Director of Late Stage Cell Culture, Pharmaceutical Technical Development, at Genentech. His group’s responsibilities include process development, process characterization & validation, and process scale-up & transfer for Phase III and commercial cell culture & fermentation processes. Prior to his current position, Dr. Kiss he was a Principal Engineer for cell culture process transfers external to Genentech (2004-2006), as Associate Director of Manufacturing Science & Technology (1998-2003), and as Senior Engineer in Cell Culture & Fermentation R&D (1993-1998). His groups developed the cell culture processes used to commercialize the monoclonal antibodies Rituxan™ and Herceptin™. He has participated in multiple biologics facility startups and process transfers up to the 25kL operational scale, and has led CMC teams to successful BLA regulatory submissions. Prior to his tenure at Genentech, Dr. Kiss served as the lead process engineer at IDEC Pharmaceuticals from 1991 to 1993 in the design of the antibody manufacturing facility which ultimately served as the product launch site for Rituxan™, the first recombinant antibody approved for the treatment of cancer. Dr. Kiss received Ph.D. / M.S. degrees in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. degree in Chemical Engineering from the University of California, Davis. He is a licensed Professional Engineer in the state of California.